Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 313

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

The future of blood‐based biomarkers for Alzheimer's disease

Open access
Henriksen, Kim, O'Bryant, Sid E., Hampel, Harald, Trojanowski, John Q., Montine, Thomas J., Jeromin, Andreas, Blennow, Kaj, Lönneborg, Anders, Wyss‐Coray, Tony, Soares, Holly, Bazenet, Chantal, Sjögren, Magnus, Hu, William, Lovestone, Simon, Karsdal, Morten A., Weiner, Michael W., Blood‐Based Biomarker Interest Group·2014·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2013.01.013
Open this paper in CoChat — free account

Abstract

Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease progression or treatment response, and most are measured in cerebrospinal fluid, which limits their applicability. With these aspects in mind, the aim of this article is to underscore the concerted efforts of the Blood‐Based Biomarker Interest Group, an international working group of experts in the field. The points addressed include: (1) the major challenges in the development of blood‐based biomarkers of AD, including patient heterogeneity, inclusion of the “right” control population, and the blood–brain barrier; (2) the need for a clear definition of the purpose of the individual markers (e.g., prognostic, diagnostic, or monitoring therapeutic efficacy); (3) a critical evaluation of the ongoing biomarker approaches; and (4) highlighting the need for standardization of preanalytical variables and analytical methodologies used by the field.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2013.01.013

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 119

  1. 10.2165/11595870-000000000-00000 · DOI · Paper page
  2. 10.1038/nm.2221 · DOI
  3. 10.1016/j.jalz.2010.06.004 · DOI
  4. 10.1038/nrd3115 · DOI · Paper page
  5. 10.1016/j.neurobiolaging.2011.09.004 · DOI
  6. Patel S., 2011, Potential peripheral biomarkers for the diagnosis of Alzheimer's disease, Int J Alzheimers Dis, 2011, 572495, 10.4061/2011/572495 · DOI
  7. 10.1111/j.1468-1331.2008.02275.x · DOI
  8. Wang Y., 2012, Will post‐translational modifications of brain proteins provide novel serological markers for dementias?, Int J Alzheimers Dis, 2012, 209409
  9. Tanne J.H., 2012, US scientists discuss early detection and treatment of Alzheimer's disease, BMJ, 344, e1068, 10.1136/bmj.e1068 · doi:10.1136/bmj.e1068
  10. Hampel H., 2007, Core candidate neurochemical and imaging biomarkers of Alzheimer's disease, Alzheimers Dement, 4, 38, 10.1016/j.jalz.2007.08.006 · DOI · Paper page
  11. 10.1111/j.1749-6632.2009.04944.x · DOI
  12. 10.1111/j.1526-4610.2011.01959.x · DOI
  13. 10.1111/j.1755-5949.2009.00104.x · DOI
  14. 10.1016/j.jalz.2011.05.900 · DOI
  15. 10.1016/j.neurobiolaging.2007.03.029 · DOI · Paper page
  16. 10.1097/WCO.0b013e3283168e1a · DOI
  17. 10.1016/S1474-4422(12)70142-4 · DOI · Paper page
  18. 10.1016/j.jalz.2012.05.2116 · DOI
  19. Jeter C.B., 2013, Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/concussion, J Neurotrauma, 30, 657, 10.1089/neu.2012.2439 · DOI · Paper page
  20. Papa L., 2013, Systematic Review of Clinical Research on Biomarkers for Pediatric Traumatic Brain Injury, J. Neurotrauma, 30, 324, 10.1089/neu.2012.2545 · DOI
  21. 10.1016/j.pneurobio.2011.04.007 · DOI
  22. 10.1212/01.wnl.0000191307.69661.c3 · DOI · Paper page
  23. 10.1056/NEJMp1208061 · DOI · Paper page
  24. 2010, World Alzheimer report 2009
  25. 10.1212/WNL.0b013e318266fa70 · DOI · Paper page
  26. Soares H.D., 2012, Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease, Arch Neurol, 69, 1310, 10.1001/archneurol.2012.1070 · DOI · Paper page
  27. Koyama A., 2013, The Role of Peripheral Inflammatory Markers in Dementia and Alzheimer's Disease: A Meta‐Analysis, J Gerontol A Biol Sci Med Sci, 68, 433, 10.1093/gerona/gls187 · DOI · Paper page
  28. 10.1016/S0140-6736(06)69113-7 · DOI · Paper page
  29. 10.1016/S1474-4422(11)70072-2 · DOI · Paper page
  30. 10.1001/archneur.58.11.1803 · DOI · Paper page
  31. Rosa G.D., 2012, Nanotechnologies: a strategy to overcome blood‐brain barrier, Curr Drug Metab, 13, 61, 10.2174/138920012798356943 · DOI
  32. 10.3233/JAD-2011-101959 · DOI
  33. 10.1007/s12017-011-8155-9 · DOI · Paper page
  34. 10.1016/j.neurobiolaging.2006.05.016 · DOI · Paper page
  35. 10.1007/s00702-009-0224-y · DOI
  36. Ghidoni R., 2013, Translational proteomics in Alzheimer's disease and related disorders, Clin Biochem, 46, 480, 10.1016/j.clinbiochem.2012.10.012 · DOI
  37. 10.1186/1471-2474-11-125 · DOI
  38. 10.1016/j.clinbiochem.2010.03.015 · DOI
  39. 10.1186/ar3280 · DOI
  40. 10.1001/archgenpsychiatry.2010.78 · DOI · Paper page
  41. 10.1093/brain/awl279 · DOI · Paper page
  42. 10.1371/journal.pone.0028527 · DOI
  43. 10.3233/JAD-2010-101350 · DOI
  44. 10.1016/j.joca.2006.04.001 · DOI · Paper page
  45. 10.1080/13547500902777608 · DOI
  46. 10.1016/j.pneurobio.2012.06.006 · DOI
  47. Britschgi M., 2011, Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome, Mol Cell Proteomics, 10, M111, 10.1074/mcp.M111.008862 · DOI
  48. 10.1111/j.1749-6632.2009.05066.x · DOI
  49. Doecke J.D., 2012, Blood‐Based Protein Biomarkers for Diagnosis of Alzheimer Disease, Arch Neurol, 69, 1318, 10.1001/archneurol.2012.1282 · DOI · Paper page
  50. 10.1371/journal.pone.0028092 · DOI · Paper page
  51. Llano D.A., 2012, Alzheimer Dis Assoc Disord
  52. 10.1016/j.hfc.2008.08.013 · DOI
  53. 10.1007/s00592-007-0014-7 · DOI
  54. 10.1016/j.biopsych.2009.01.032 · DOI
  55. 10.4088/JCP.09m05872oli · DOI
  56. 10.1002/jnr.23122 · DOI · Paper page
  57. 10.1186/alzrt103 · DOI · Paper page
  58. Mielke M.M., 2011, Plasma Sphingomyelins are Associated with Cognitive Progression in Alzheimer's Disease, J Alzheimers Dis, 27, 259, 10.3233/JAD-2011-110405 · DOI
  59. Booij B.B., 2011, A gene expression pattern in blood for the early detection of Alzheimer's disease, J Alzheimers Dis, 23, 109, 10.3233/JAD-2010-101518 · DOI
  60. Rye P.D., 2011, A novel blood test for the early detection of Alzheimer's disease, J Alzheimers Dis, 23, 121, 10.3233/JAD-2010-101521 · DOI
  61. Fehlbaum‐Beurdeley P., 2012, Validation of AclarusDx, a Blood‐Based Transcriptomic Signature for the Diagnosis of Alzheimer's Disease, J Alzheimers Dis, 32, 169, 10.3233/JAD-2012-120637 · DOI
  62. Lunnon K., 2013, A Blood Gene Expression Marker of Early Alzheimer's Disease, J Alzheimers Dis, 33, 737, 10.3233/JAD-2012-121363 · DOI
  63. Lunnon K., 2012, Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood, J Alzheimers Dis, 30, 685, 10.3233/JAD-2012-111592 · DOI
  64. 10.1371/journal.pone.0002698 · DOI · Paper page
  65. 10.1016/j.jalz.2010.06.001 · DOI
  66. 10.1016/j.jalz.2009.05.666 · DOI
  67. 10.1016/j.exger.2011.11.012 · DOI
  68. 10.1093/gerona/glr185 · DOI
  69. Holtzman D.M., 2011, Mapping the road forward in Alzheimer's disease, Sci Transl Med, 3, 10.1126/scitranslmed.3003529 · DOI
  70. 10.1016/j.autrev.2010.07.008 · DOI
  71. 10.1016/j.exger.2009.10.003 · DOI
  72. Maftei M., 2012, Antigen‐Bound and Free beta‐Amyloid Autoantibodies in Serum of Healthy Adults, PLoS One, 7, e44516, 10.1371/journal.pone.0044516 · DOI
  73. 10.1371/journal.pone.0023112 · DOI
  74. 10.1016/j.expneurol.2011.11.026 · DOI · Paper page
  75. 10.1007/s00401-011-0861-8 · DOI · Paper page
  76. 10.1001/archneurol.2011.1841 · DOI · Paper page
  77. Hampel H., 2012, Biological markers of amyloid beta‐related mechanisms in Alzheimer's disease, Exp Neurol, 223, 334, 10.1016/j.expneurol.2009.09.024 · DOI · Paper page
  78. 10.1007/s00702-012-0772-4 · DOI
  79. 10.3233/JAD-2011-101977 · DOI
  80. Watt A.D., 2012, Variability in blood‐based amyloid‐beta assays: the need for consensus on pre‐analytical processing, J Alzheimers Dis, 30, 323, 10.3233/JAD-2012-120058 · DOI
  81. 10.3233/JAD-2011-111421 · DOI
  82. 10.1001/archneurol.2008.565 · DOI · Paper page
  83. 10.1007/s00415-011-5960-x · DOI
  84. 10.1007/s12031-010-9403-4 · doi:10.1007/s12031-010-9403-4
  85. 10.1016/j.jss.2008.12.022 · DOI
  86. Neselius S., 2012, Brain Injury
  87. Portelius E., 2010, A novel Abeta isoform pattern in CSF reflects gamma‐secretase inhibition in Alzheimer disease, Alzheimers Res Ther, 2, 7, 10.1186/alzrt30 · DOI
  88. 10.1371/journal.pone.0031084 · DOI
  89. 10.1074/jbc.M111.234674 · DOI
  90. 10.1073/pnas.1630428100 · DOI · Paper page
  91. 10.1016/j.brainres.2008.06.094 · DOI
  92. 10.1523/JNEUROSCI.3421-07.2007 · DOI · Paper page
  93. 10.1186/1750-1326-4-9 · DOI · Paper page
  94. Grimm M.O., 2012, The role of APP proteolytic processing in lipid metabolism, Exp Brain Res, 217, 365, 10.1007/s00221-011-2975-6 · DOI
  95. 10.1038/nrneurol.2010.157 · DOI
  96. 10.1074/jbc.M503341200 · DOI · Paper page
  97. 10.1515/CCLM.2011.077 · DOI
  98. 10.2353/ajpath.2007.061232 · DOI · Paper page
  99. Yang C., 2012, The C‐terminal TDP‐43 fragments have a high aggregation propensity and harm neurons by a dominant‐negative mechanism, PLoS One, 5, e15878, 10.1371/journal.pone.0015878 · DOI · Paper page
  100. 10.1016/S1474-4422(10)70195-2 · DOI · Paper page
  101. 10.1016/j.yexcr.2011.06.017 · DOI
  102. K.Henriksen Y.Wang M.G.S⊘rensen N.Barascuk J.Suhy J.T.Pedersen et al.An enzyme‐generated fragment of Tau measured in serum shows an inverse correlation to cognitive function.PLOS One 2013 In press · DOI
  103. 10.1136/ard.2005.051292 · DOI
  104. 10.1186/1472-6904-8-12 · DOI
  105. 10.1002/art.21977 · DOI · Paper page
  106. 10.1016/j.joca.2008.03.006 · DOI
  107. 10.1210/jc.74.3.476 · DOI · Paper page
  108. 10.1016/j.joca.2005.05.004 · doi:10.1016/j.joca.2005.05.004
  109. 10.1111/j.1365-2125.2009.03371.x · DOI
  110. U.S. Food and Drug Administration, 2001, Guidance for industry: bioanalytical method validation
  111. Belabani C., 2013, A condensed performance‐validation strategy for multiplex detection kits used in studies of human clinical samples, J Immunol Methods, 387, 1, 10.1016/j.jim.2012.08.002 · DOI
  112. 10.17226/13297 · DOI · Paper page
  113. 10.1016/j.trsl.2012.01.009 · DOI · Paper page
  114. 10.1093/bmb/ldr043 · DOI
  115. 10.1001/archneurol.2007.29 · DOI · Paper page
  116. 10.1016/j.molmed.2011.06.004 · DOI · Paper page
  117. 10.1212/WNL.0b013e3182343365 · DOI
  118. 10.1016/j.biopsych.2004.07.021 · DOI · Paper page
  119. 10.1093/hmg/dds296 · DOI · Paper page

Cited by

See all 313

Metadata

Authors
Henriksen, K., O'Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H., Bazenet, C., Sjögren, M., Hu, W., Lovestone, S., Karsdal, M. A., Weiner, M. W., & Blood‐Based Biomarker Interest Group
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2013-07-15
Volume
10
Issue
1
Pages
115-131
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2013.01.013
OpenAlex
W1968790254
Cited by
313
References
21
FWCI
17.65
Type
journal article
Language
en
Open access
green
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Funders
  • Vetenskapsrådet (14002)
  • National Institutes of Health
  • National Institute on Aging (R01AG039389)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The future of blood‐based biomarkers for Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2013.01.013
The paper
Henriksen, K., O'Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H., Bazenet, C., Sjögren, M., Hu, W., Lovestone, S., Karsdal, M. A., Weiner, M. W., & Blood‐Based Biomarker Interest Group. (2014). The future of blood‐based biomarkers for Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2013.01.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.